Patients & families

Our commitment

At Mariana Oncology, a Novartis company, we see and understand what it means to have cancer. We know that the fear of cancer treatment is sometimes greater than the fear of the disease itself.

We are driven, not only to develop better, more effective therapies, but treatments that preserve humanity, dignity, and life. We can redefine what it means to have cancer, and we work each day to meet this urgent need. For us, it’s not enough to be first; we seek to be best—delivering the best therapeutic solution for the cancers we treat.

Mariana Oncology scientist smiling as they stand in front of a fume hood in the laboratory
waves
We act with intention. We move with agility. And we maintain our focus on the end goal—to forever transform cancer treatment.

Advancing a new standard in cancer treatment

We understand that a cancer diagnosis doesn’t just affect a person’s health, but every aspect of life. We believe radioligand therapies offer a therapeutic profile that is well-suited to effectively treating cancer while allowing patients to maintain their daily lives and focus on what matters most to them.

Illustration depicting traditional radiation therapy in which external beams are irradiating the lungs, heart, and liver

Traditional radiation therapy

Radiation therapy has long been used to treat cancer by directing an external beam of radiation at the tumor, which destroys cancer cells. This traditional, localized approach, though highly effective, also affects nearby healthy tissue and can lead to unwanted side effects; it is not well suited to address cancers that have spread to different parts of the body.

Illustration depicting how Mariana Oncology’s systemically delivered radioligand therapies precisely deliver radiation to cancer cells in the body

Mariana Oncology’s radioligand therapies

Our radioligand therapeutic candidates are systemically delivered treatments that combine a radioactive particle with a targeting molecule that seeks out proteins or markers found primarily on cancer cells. The radioligand is designed to lock onto the cancer cells to directly deliver radiation that causes critical cell damage. This precision delivery is expected to maximize the therapeutic effect of the medicine while limiting exposure to healthy tissues, avoiding a key challenge associated with more traditional methods of delivering radiation.

Treatments in development

Mariana Oncology, a Novartis Company, is rapidly advancing a pipeline of innovative radioligand therapies into clinical trials with the hopes of addressing a broad range of cancers. We plan to initiate early phase clinical trials in 2025.

Turning innovation into impact

Explore our programs